Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss drug plus exercise may protect muscle in women

NCT ID NCT07457437

Disease control Sponsor: University of Exeter Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding a structured exercise program to the weight-loss drug tirzepatide can help overweight and obese women maintain muscle mass and physical function. Sixty women aged 25-50 will take tirzepatide for 20 weeks; half will also follow a progressive resistance exercise routine. The goal is to see if exercise prevents muscle loss during weight loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide (a weight-loss drug) and a progressive resistance exercise program
What this could lead to
If it works, this could show that combining exercise with tirzepatide helps women lose fat while preserving muscle and strength, leading to better overall health.
What could go wrong
This is a small, early-stage study with only 60 participants. The exercise program is supervised and may not reflect real-world results. Tirzepatide can cause side effects like nausea and vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 25-50 years old * BMI ≥27 kg/m2 with one obesity related co-morbidity or a BMI between ≥30 and 35 kg/m2 * Female Exclusion Criteria: * Previous GLP-1RA use * Diabetes (Type 1 and 2) * Contraindicative health condition to GLP-1/GIP * Fail clinically administered health screening form for tirzepatide prescription * Pregnant or wanting to become pregnant in the next 6 months * Has or has previously had an eating disorder * Inability to perform exercise program and exercise tests * Advised not to exercise by their general practitioner or medical professional * Current or recent injury within the last 6 months that may affect the ability to carry out resistance exercise * Has consistently resistance trained previously (\>10 sessions per year) * Currently taking medication or supplements that have been shown to impact muscle function and muscle mass in the last 6 months * Current or recent, ≤6 months, smoker * Currently on HRT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle mass and strength are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscle mass and strength Obesity & overweight Physical function

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nutritional Physiology Research Unit

    RECRUITING

    Exeter, Devon, EX2 4TH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.